Drugs / Lactobacillus salivarius PS2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT01505361 | Nov 2011 → Mar 2012 | mastitis | Universidad Complutense de Madrid | Unknown | Met primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT01124448 Comparator | Mar 2011 → Sep 2013 | mastitis | Universidad Complutense de Madrid | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus salivarius PS2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01505361 ↗ |
| Known as | L. salivarius PS2 | “Those in the probiotic group (n = 55) ingested daily 9 log10 colony-forming units of L. salivarius PS2 from approximately week 30 of pregnancy until delivery” PMID 26611780 ↗ Nov 2015 |
| Modality | Other / unclassified | “probiotic strain” NCT01124448 ↗ |
| Route | Oral | “oral route” NCT01124448 ↗ |